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Abstract
The first Keystone symposium on the role of microenvironment in
tumor induction and progression attracted 274 delegates from 13
countries to Banff in the heart of the Canadian Rockies. The
meeting was organized by Mina Bissell, Ronald DePinho and Luis
Parada, and was held concurrently with the Keystone symposium
on cancer and development, chaired by Matthew Scott and
Roeland Nusse. The 30 oral presentations and over 130 posters
provided an excellent forum for discussing emerging data in this
rapidly advancing field.
Introduction
It is now apparent that reciprocal interactions between tumor
cells and their microenvironment — extracellular matrix (ECM),
growth factors, fibroblasts, immune and endothelial cells —
play an essential role in the earliest stages of transformation
to malignant progression and metastasis. By better
understanding the complex interactions between all of these
factors, it is hoped that therapies might be effectively
targeted against both epithelial and stromal determinants of
tumor progression. In this regard, there were several
encouraging presentations on novel clinical approaches that
target these processes.
Skiers and snowboarders among the delegates were blessed
with 67 cm of fresh snow just prior to arrival, resulting in a
stampede for the ski buses each day at 11 am. The quality of
the meeting was perhaps best reflected by an equally urgent
stampede back to the conference center in time for the
evening sessions and posters.
Zena Werb (University of California, San Francisco) set the
scene for the meeting with a wide ranging plenary lecture
detailing crucial interactions between epithelial and stromal
cells during both normal mammary development and
tumorigenesis. She described a series of wild-type/knockout
tissue recombination experiments used to dissect the
requirements for epithelially and stromally expressed growth
factors and receptors in mammary gland development. In a
lecture that was both visually and intellectually stimulating,
she showed that intravital imaging technology is a valuable
tool with which to interrogate the interactions between
stromal and epithelial cells in tumorigenesis. Time-lapse
fluorescent videos using mouse mammary tumor virus-polyoma
middle T antigen (MMTV-PyMT) transgenic mice bearing
various fluorescent markers demonstrated the dynamic inter-
actions between the tumor and host cellular components.
In the second keynote address, Joan Massagué (Memorial
Sloan Kettering Cancer Center, New York), described a
series of experiments that probed the nature of pre-metastatic
cells. Cells from primary tumors in specific organs tend to
have a tropism for successful metastasis to distant sites (e.g.
breast cancer to bone, lung, liver, and brain; and colon
cancer to liver). To what extent are these preferences pre-
specified in the primary tumor cell population? To address
this question, Massagué used a metastatic breast cancer cell
line, MDA-MB-231, and used nude mice as a ‘cell sorter’ by
introducing cells and collecting and testing those that
established metastatic colonies in particular organs. He
showed that this cell line is indeed composed of
subpopulations with distinct metastatic characteristics that
correlate with particular transcriptional profiles [1]. He has
begun to analyze the functional relevance of these
correlations in overexpression and small interfering RNA
(siRNA) studies.
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Angiogenesis and microenvironment
The Monday morning session focused on the role of the
microenvironment during angiogenesis. The speakers
described the regulation of angiogenesis, both by
transcriptional programs and by extracellular pro- and anti-
angiogenic factors, and the mechanisms by which tumor
angiogenesis might be effectively targeted.
The first speaker, Luisa Iruela-Arispe (University of California,
Los Angeles), presented work from her group showing that
transgenic overexpression of thrombospondin-1 (TSP-1), an
ECM component with anti-angiogenic activity, inhibits angio-
genesis and tumor growth in MMTV-Neu mice, and effects a
downregulation of matrix metalloproteinase (MMP)-9 and
decreased expression of vascular endothelial growth factor
(VEGF) [2]. Dr Iruela-Arispe’s lab is now working to delineate
the different functions of a series of different metallo-
proteinase cleavage fragments of VEGF in tumor angiogenesis.
Nancy Boudreau (University of California, San Francisco)
discussed two homeobox transcription factors, HoxD3 and
HoxD10, and their apparently opposing roles in breast cancer
(Carrio  et al., manuscript submitted). HoxD3, which is not
expressed in the normal mammary gland, is upregulated
during breast cancer progression and upregulates several
ECM remodeling enzymes and angiogenic factors, including
VEGF [3]. In contrast, Hox D10, a potent inhibitor of
angiogenesis, is highly expressed in the normal gland and is
absent in invasive carcinomas [4]. Currently, Boudreau and
colleagues are concentrating on the organizational role that
Hox D10 plays in the normal mammary gland using three-
dimensional culture assays.
Rapidly growing tumors are frequently hypoxic, and
neoangiogenesis may be stimulated by hypoxia-dependent
transcriptional activation. Randall Johnson (University of
California, San Diego) described the effect of tissue-specific
ablation of hypoxia inducible factor 1α (HIF-1α) in endothelial
cells. Loss of HIF-1α blocked neoangiogenesis in in vivo
matrigel plug assays and also resulted in impaired wound
healing in these mice. Most strikingly, tumor xenografts in
these mice were smaller and more necrotic than in controls,
resulting from a greatly reduced microvessel density [5].
A short talk given by Gavin Thurston (Regeneron
Pharmaceuticals, Tarrytown, NY) provided a summary of the
array of drugs in development to target VEGF signaling. He is
currently studying the efficacy of a decoy receptor for VEGF,
‘VEGF-TRAP’, against angiogenesis in vivo and has shown
that this treatment causes decreased tumor burden in the
RIP-TAG transgenic mouse model.
Mary Hendrix (Children’s Memorial Research Center at
Northwestern University, Chicago) described an alternative to
angiogenesis used by aggressive melanoma cells, termed
vasculogenic mimicry. In this process, these melanoma cells
organize to form ECM-rich fluid conducting ductal networks
within the tumor, lined by the tumor cells themselves and
connected to the vasculature of the host. This reorganization
of the tumor cells facilitates the supply of oxygen and
nutrients. Hendrix also showed that these networks are
resistant to classical inhibitors of angiogenesis, such as
endostatin [6].
Microenvironmental influences on metastasis
Interactions between tumor cells and cellular or
proteinaceous components of their microenvironment may
inhibit or facilitate metastasis. In this evening session, the
speakers discussed some of the signaling events involved
and the identification of pro-metastatic transcriptional
programs.
Large numbers of tumor-infiltrating macrophages often
correlate with poor prognosis. Jeffrey Pollard (Albert Einstein
College of Medicine, New York) described his laboratory’s
work on colony stimulating factor 1 (CSF1), a protein
secreted by tumor cells that acts as a potent chemoattractant
for macrophages. Knockout of CSF1 attenuated macrophage
recruitment in the MMTV-PyMT mammary tumor model,
resulting in a delayed progression to metastasis of these
tumors. Conversely, tumor progression and metastasis were
accelerated by CSF1 overexpression in the same model.
Thus, CSF1 is implicated in recruiting these VEGF, MMP,
and protease secreting pro-angiogenic immune cells to the
tumor, which facilitates tumor progression [7].
Kenneth Pienta (University of Michigan, Ann Arbor) presented
gene and protein expression data from primary and
metastatic prostate cancers from a series of 32 rapid ‘warm’
autopsies. While bone represented the most common site of
metastasis, non-osseous sites included lymph nodes, liver,
lung, and adrenal gland. Metastases to different sites (from
the same primary tumor) frequently showed significant
differences in histology and gene expression [8]. Thus a
single regimen might not reasonably be expected to treat
such a heterogeneous disease. Pienta outlined an aggressive
multi-targeted chemotherapy approach that he is testing in
this patient population.
Using an approach similar to that outlined by Joan Massagué,
Richard Hynes (Massachusetts Institute of Technology,
Cambridge) isolated lung metastases formed following tail
vein injection of melanoma cell lines [9]. Successive isolation
and re-injection selected for a highly lung-tropic population.
Gene expression analysis revealed several changes
compared to the parental population. Hynes discussed in
detail his analysis of one such gene, which encodes an
orphan G-protein coupled receptor (GPR56) with a role in
adhesion signaling, that was downregulated in the metastatic
variant. Restoration of expression of this gene, while not
altering cell growth rate in vitro, significantly attenuated the
metastatic potential of these cells.115
Breast cancer soon after pregnancy is associated with high
rates of metastasis and poor survival. Pepper Schedin
(University of Colorado Health Sciences Center, Denver)
described an analysis of the differing phenotypic effects
induced in breast cancer cells by purified extracellular
matrices from non-parous, parous, and involuting rat mammary
glands. The involution matrix, which was enriched in
fibronectin fragments, promoted breast cancer cell invasion
and metastasis, whereas the other matrices suppressed these
phenotypes. Addition of fibronectin fragments to these other
matrices was sufficient to elicit the invasive phenotype [10].
Stromal-epithelial and heterotypic interactions
This session focused on reciprocal paracrine interactions
between stromal and epithelial cells in tumor progression.
Using a variety of models, speakers discussed the effects of
stromally secreted factors on tumor initiation and progression.
Harold Moses (Vanderbilt University, Nashville) described the
complexity of transforming growth factor β (TGFβ) signaling
in cancer progression. Specific ablation of transforming
growth factor β receptor 2 (TGFβR2) in mammary epithelium
resulted in lobuloalveolar hyperplasia and, in an MMTV-PyMT
background, reduced tumor latency and enhanced
metastases. Knockout of TGFβR2 in stromal fibroblasts (by
crossing with FSP1-Cre) resulted in hyperproliferation of
adjacent epithelia and tumorigenesis in several organs, a
striking demonstration of the power of stromal changes to
effect epithelial transformation. Paracrine stimulation of
epithelial cells by stromally produced hepatocyte growth
factor (HGF) has been implicated in this phenotype [11].
Leland Chung (Emory University School of Medicine, Atlanta)
is investigating the mechanisms by which prostate cancer
cells interact with bone stromal cells during osseous
metastasis. Chung reported that reciprocal interactions
between prostate cancer cells and bone stromal fibroblasts in
three-dimensional cultures accentuate the growth and
invasion of the tumor cells in vitro and  in vivo [12]. In a
process termed osteomimicry, these metastatic prostate
cancer cells invade normal bone tissue by upregulating bone
matrix proteins such as osteocalcin, osteopontin, osteonectin,
and bone-sialoprotein. His group determined that a soluble
factor secreted by both bone and prostate cancer cells, β2-
microglobulin, controls the expression of these bone matrix
proteins and is upregulated during prostate cancer invasion
into bone.
Mary Helen Barcellos-Hoff (Lawrence Berkeley National
Laboratory, Berkeley) discussed radiation carcinogenesis in
terms of its effects on microenvironment during cancer
initiation and progression. Using the mouse mammary gland
as a model, she described the effect of ionizing radiation on
the mammary stroma and its contribution to neoplastic
behavior. The genomic changes that accumulate in tumors
forming in irradiated hosts are now being investigated.
Olivier de Wever (University Hospital Ghent, Ghent) is
studying the role of the stromal myofibroblasts in cancer
invasion. Myofibroblasts from colon cancer tissue promote
the invasiveness of colon cancer cells in in vitro assays by
secretion of scatter factor/hepatocyte growth factor (SF/
HGF) and tenascin C (TNC), which lead to downregulation of
RhoA and upregulation of Rac activity [13]. De Wever and
colleagues [14] also showed that TGFβ secreted by colon
cancer cells stimulates invasion by stromal myofibroblasts in
vitro in a c-jun amino-terminal kinase (JNK)-dependent
manner. Myofibroblast N-cadherin was essential for this
process.
Recent advances in signaling in 3D
microenvironments
Researchers are increasingly taking advantage of sophisticated
physiological culture systems to model in vivo biological
processes.
Joan Brugge (Harvard Medical School, Boston) presented
data on her laboratory’s extensive analysis of the effect of
oncogenes and tumor suppressors on mammary epithelial
morphogenesis in a three-dimensional matrigel culture assay.
Brugge’s lab has transduced MCF10A cells with 1000
cancer-related genes. These cells span the full spectrum of
cancer related phenotypes — escape from growth arrest,
filling of lumen, loss of tissue polarity, alterations in cell
polarity, disruption of cell-cell junctions, and acquisition of
invasive behavior. The amenability of these cultured mammary
acini to genetic manipulation has allowed Brugge to begin to
address the cooperative (and antagonistic) effects between
various pathways.
Valerie Weaver (University of Pennsylvania, Philadelphia)
explored the role of mechanotransduction in mammary
epithelial morphogenesis and transformation. She showed
that stiffness (viscoelastic modulus) increases in vivo during
progression from the normal to transformed mammary gland.
In a series of in vitro three-dimensional culture assays using
gels of defined viscoelastic properties, she demonstrated that
modulating the stiffness of the microenvironment can indeed
alter the phenotype of breast epithelial cells by altering
signaling homeostasis, with increasing stiffness leading to
increasingly transformed behavior.
John Muschler (California Pacific Medical Center, San
Francisco) described his work on the functional characteriza-
tion of the ECM receptor, dystroglycan, in mammary epithelial
cells. His laboratory has previously demonstrated a loss of
dystroglycan function in several human breast cancer cell
lines. Here, using a conditional knockout of dystroglycan in
cultured cells, Muschler and colleagues defined an essential
role for dystroglycan in signaling from laminin-1. Recruitment
and assembly of laminin-1 to the cell surface required
dystroglycan expression, as did subsequent signals from
laminin-1 for cell polarity and tissue specific gene expression.
Available online http://breast-cancer-research.com/contents/7/3/113116
Edna Cukierman (Fox Chase Cancer Center, Philadelphia)
described a three-dimensional culture model system of
stroma derived from tumor-associated fibroblasts at various
stages of cancer progression. Cell signaling events within
these matrices differ from those occurring on plastic
substrata. Removal of tumor-associated fibroblasts from
these cultures and addition of normal fibroblasts to the matrix
resulted in upregulation in these cells of markers associated
with tumor fibroblasts.
Cancer models
In this session, a number of sophisticated cancer models
were presented and the implications of the derived data were
discussed.
Ronald DePinho (Dana-Farber Cancer Institute, Boston)
presented a succession of transgenic mouse models of
pancreatic adenocarcinoma that closely reflect the stages of
progression seen in the human disease. Using a series of
floxed alleles on a PDX-Cre background he delineated a
successive requirement for K-Ras activation, Ink4A/Arf loss
and p53 loss in pancreatic cancer progression [15]
Elaine Fuchs (Rockefeller University, New York) described
her laboratory’s characterization of epidermal stem cells.
Using transgenic mice with a histone 2B-GFP fusion under
the control of a K5-rtTA transgene, Fuchs and colleagues
employed a pulse-chase strategy to label these infrequently
cycling cells in the skin. These cells, located in the bulge of
the hair follicle, are mobilized to proliferate upon wounding
or at the start of each new hair cycle. Isolation of these
label-retaining cells for further characterization revealed that
they form larger colonies in culture than their transit-
amplifying progeny and they retain the capacity to
reconstitute epidermis, sebaceous glands, and hair follicles
in transplant experiments [16,17].
Epigenetic changes frequently accompany genomic changes
during tumor progression. Rudolf Jaenisch (Massachusetts
Institute of Technology, Cambridge) described attempts to
generate embryonic stem (ES) cells by transferring tumor cell
nuclei to enucleated oocytes. While this process was
extremely inefficient, a single ES cell line was obtained from a
malignant melanoma nucleus [18]. In a striking parallel with
the decades-old work of Beatrice Mintz [19], melanoma-
derived ES cells gave rise to normal appearing chimeric mice.
Despite the subsequent onset of melanomas, these studies
provide a remarkable demonstration of the reversibility of the
cancer phenotype.
Following up on earlier observations that deregulated
expression of MMP-3 in transgenic mice could lead to
genomic instability and mammary tumorigenesis [20], Derek
Radisky (Lawrence Berkeley National Laboratory, Berkeley)
provided detailed insight into the mechanism underpinning
this phenomenon. He showed that MMP-3 promotes
cytoskeletal changes that lead to upregulation of reactive
oxygen species that are both necessary and sufficient to
induce epithelial to mesenchymal transition, oxidative DNA
damage, and genomic instability.
The zebrafish offers several advantages as a model organism
in cancer biology. Testicular germ cell tumors (TGCTs) in
zebrafish share certain similarities with the human disease,
such as post-pubertal onset, an apparent premalignant in situ
lesion, and sensitivity to radiation treatment. James Amatruda
(Southwestern Medical Center, Dallas) and colleagues have
identified a highly penetrant, dominantly inherited mutation
that causes TGCTs in zebrafish and are using interval
haplotype mapping to narrow down the locus and clone the
mutated gene.
The extracellular matrix and its degrading
enzymes in tumor progression and metastasis
MMPs have long been of interest to cancer biologists for their
ability to degrade components of the ECM and to shed cell
surface ligands. Lynn Matrisian (Vanderbilt University School
of Medicine, Nashville) collaborated with Mitsuru Futakuchi
(Universities of Nebraska and Nagoya, Japan) to study
prostate cancer growth in the bone microenvironment by
transplanting chemically induced prostate cancer cells into
the cranium and spines of syngeneic F344 rats. Genes
commonly found in human prostate-to-bone metastasis,
including  PTHrP,  RANKL, and OPG, were upregulated.
MMP-7 was identified as being highly expressed in
osteoclasts in areas of high osteolysis. Matrisian’s lab further
determined that MMP-7 selectively cleaves and releases a
soluble form of RANKL, a potent activator of osteolysis found
primarily on the surface of osteoblasts. MMP-7 solubilized
RANKL was capable of activating osteoclasts and resorbing
dentin discs. Immunodeficient MMP-7-null mice showed a
significant decrease in osteolysis compared to controls,
suggesting that MMP-7 plays a role in bone resorption during
prostate metastasis to bone through solubilization of RANKL.
Raghu Kalluri (Harvard Medical School, Boston) began by
describing a ‘degradomics’ analysis of proteolytic cleavage
fragments of extracellular matrix proteins. Of 166 fragments
identified, 14 possessed anti-angiogenic activity. He focused
on tumstatin, a C-terminal fragment of type IV collagen. Mice
lacking the gene encoding this collagen chain experienced
enhanced angiogenesis during tumor progression, which was
restored to normal by injection with recombinant tumstatin
[21,22]. Similarly, tumorigenesis was accelerated in mice
defective in MMP-9 (which cleaves collagen IV to release
tumstatin) on both MMTV-Neu and APCmin backgrounds.
Conversely, transgenic mice overexpressing either tumstatin
or endostatin were significantly protected from tumorigenesis.
Seth Schor (University of Dundee) presented an interesting
talk on the identification of a secreted protein that underlies
the fetal fibroblast phenotype described 20 years ago by his
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laboratory. Migration stimulating factor 1 (MSF1) is a splice-
variant of fibronectin that produces a truncated isoform that
corresponds approximately to the most amino-terminal
70 kDa [23]. Although this isoform is not expressed in normal
adult fibroblasts, it is expressed in both tumor-associated and
fetal fibroblasts, where it exerts a potent motogenic effect at
femtomolar levels. Multiple cell types respond to MSF-1,
which may promote malignant potential.
James Quigley (Scripps Research Institute, La Jolla)
described a model in which tumor cells in collagen onplants
on the chorioallantoic membrane of chick embryos stimulate
angiogenesis in an MMP-dependent fashion as well as
intravasate and metastasize. Species-specific reagents were
used to delineate the contribution of various host and tumor
proteins and cell types, with MMP-9 and MMP-13 provided
by the chicken heterophils and macrophages, respectively,
playing particularly important roles [24].
Role of inflammatory cells and cytokines in
the tissue and tumor microenvironment
A prevailing theme throughout the meeting was the diverse
contributions made by cells of the immune system to tumor
progression and metastasis. In this session, the speakers
used elegant transgenic mouse models to delineate these
functions. The session concluded with a presentation
detailing the transcriptional profile of each of the cell types in
the breast tumor microenvironment.
Luis Parada (University of Texas Southwestern Medical
School, Dallas) presented a series of mouse models of brain
tumors, both neurofibromas and glioblastomas, resulting
from deletion of the tumor suppressor NF1. These models,
which closely mimic many aspects of the human disease,
also shed light on the role of the heterozygous status of non-
tumor host cells during malignant progression in patients
with this familial cancer syndrome. The outcome of NF1
deletion in schwann cells depended on the status of the
NF1 alleles in the adjacent stroma [25]. NF1–/– schwann
cells preferentially enhance the proliferation of NF1+/– mast
cells which infiltrate the tumor — these in turn enhance tumor
growth. In contrast, the onset of NF1–/– tumors was
suppressed when the surrounding stromal cells retain both
wild-type NF1 alleles.
Douglas Hanahan (University of California, San Francisco)
analyzed the contribution of stromal factors to angiogenesis
in a mouse cervical carcinoma model in which the HPV16
early region is expressed from the K14 promoter. Crossing
these mice with mice null for MMP-9 resulted in smaller, less
vascularized tumors. Expression of MMP-9 by tumor-
infiltrating macrophages was implicated in the promotion of
angiogenesis. He demonstrated that zoledronic acid
treatment can effectively target MMP-9 expression and
activity in macrophages, resulting in a reduced interaction
between VEGF and its receptor [26].
Using the same K14-HPV16 model of squamous cell carcino-
genesis, this time concentrating on the skin, Lisa Coussens
(University of California, San Francisco) described a
requirement for cells of the adaptive immune system for the
recruitment of cells of the innate immune system to the tumor
site, where they promote tumor progression by secretion of
proteases and cytokines. Crossing these mice onto
backgrounds deficient in different lineages of T and B cells
allowed her to define a critical requirement for B lymphocytes
for mast cell recruitment to the tumor site.
In a transcriptional profiling tour de force, Kornelia Polyak
(Dana-Farber Cancer Institute, Boston) prospectively isolated
each of the cell types that comprise normal breast tissue, as
well as those from both in situ and invasive carcinoma, and
determined the gene expression profile of each population
using serial analysis of gene expression [27]. Although
genetic changes were only detected in tumor epithelial cells,
all cell types underwent significant gene expression changes,
with frequent alterations detected in genes encoding
receptors and secreted proteins. Her subsequent analysis
focused on an orphan chemokine, CXCL14, that binds
epithelial cells in vivo and in vitro and promotes the migration
and invasion of MDA-MB-231 cells in culture.
Concluding session
The final talk from Judah Folkman (Children’s Hospital,
Boston) was a fitting conclusion to a most stimulating
meeting. Dr Folkman provided both an historical perspective
on the field of angiogenesis and an inspiring discussion of the
future of therapeutics: drugs that directly block angiogenesis
signaling pathways as well as drugs that increase production
of endogenous angiogenesis inhibitors. Lastly, he described
a model in which different subpopulations of tumor cells are
inherently angiogenic and non-angiogenic. Although prolif-
erating at the same rate in vitro, only angiogenesis-competent
tumor cells formed tumors in nude mice, whereas their non-
angiogenic counterparts formed microscopic dormant
growths [28].
The critical contribution of microenvironmental factors to
tumor progression is now widely appreciated. Interest in this
field is growing and research is now advancing rapidly. We
expect that this Keystone symposium will be the first of many
more meetings that highlight the perspective of cancer
biologists who view cancer as a disease of tissues, as well as
of cells.
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